Ken Griffin Arcutis Biotherapeutics, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 85,000 shares of ARQT stock, worth $676,600. This represents 0.0% of its overall portfolio holdings.

Number of Shares

85,000

Previous 9,900 758.59%

Holding current value

$676,600

Previous $31,000 2616.13%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$3.25 - $11.77 $6.22 Million - $22.5 Million	1,914,270 New	1,914,270 $19 Million
Q3 2023 Nov 14, 2023	BUY	$5.31 - $10.98 $1.04 Million - $2.15 Million	196,127 Added 360.47%	250,535 $1.33 Million
Q2 2023 Aug 14, 2023	SELL	$7.51 - $15.0 $1.63 Million - $3.26 Million	-217,113 Reduced 79.96%	54,408 $518,000
Q1 2023 May 15, 2023	BUY	$10.23 - $17.14 $2.68 Million - $4.49 Million	261,888 Added 2718.65%	271,521 $2.99 Million
Q4 2022 Feb 14, 2023	SELL	$13.96 - $20.4 $989,512 - $1.45 Million	-70,882 Reduced 88.04%	9,633 $142,000

Q3 2022 Nov 14, 2022	SELL	$17.85 - $26.95 $2 Million - $3.02 Million	-111,996 Reduced 58.18%	80,515 $1.54 Million
Q2 2022 Aug 15, 2022	BUY	$16.33 - $22.2 $258,193 - $351,004	15,811 Added 8.95%	192,511 $4.1 Million
Q1 2022 May 16, 2022	SELL	$14.38 - $22.79 $1.01 Million - $1.6 Million	-70,215 Reduced 28.44%	176,700 $3.4 Million
Q4 2021 Feb 14, 2022	SELL	$14.98 - $25.5 $284,874 - $484,933	-19,017 Reduced 7.15%	246,915 $5.12 Million
Q3 2021 Nov 15, 2021	SELL	$19.28 - $27.1 $3.39 Million - $4.76 Million	-175,580 Reduced 39.77%	265,932 $6.35 Million
Q2 2021 Aug 16, 2021	SELL	$24.42 - $34.75 $267,252 - $380,304	-10,944 Reduced 2.42%	441,512 $12 Million
Q1 2021 May 17, 2021	BUY	$24.47 - $36.98 $7.8 Million - $11.8 Million	318,753 Added 238.4%	452,456 $13.1 Million
Q4 2020 Feb 16, 2021	BUY	$17.82 - $31.73 $2.11 Million - $3.76 Million	118,353 Added 771.03%	133,703 $3.76 Million
Q3 2020 Nov 16, 2020	SELL	$23.44 - $32.28 $415,802 - $572,614	-17,739 Reduced 53.61%	15,350 $450,000
Q2 2020 Aug 14, 2020	SELL	$24.48 - $36.56 $550,212 - $821,722	-22,476 Reduced 40.45%	33,089 $1 Million
Q1 2020 May 15, 2020	BUY	$18.5 - $36.9 $1.03 Million - $2.05 Million	55,565 New	55,565 $1.66 Million

Others Institutions Holding ARQT

# of Institutions

173

Shares Held

126M

Call Options Held

498K

Put Options Held

1.64M

View Full List

About Arcutis Biotherapeutics, Inc.

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $479M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

More about ARQT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account